melbourne, australia, December 5, 2022 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announced the appointment and promotion of several key executives, reflecting the company’s increased commercial focus and continued succession planning will be announced.
Richard Valeix promoted to Group Chief Commercial Officer
Telix Europe Middle East and Africa (EMEA) Business since joining Telix May 2021, was appointed to the newly created position of Group Chief Commercial Officer. This key global leadership role includes the global expansion of Illuccix and the launch of TLX250-CDx, Telix’s kidney cancer imaging agent, for which Telix recently reported positive Phase III data. Oversees the commercialization strategy and activities of Telix’s late-stage pipeline assets.
Richard is an experienced business leader with experience in marketing, sales and general management at a major pharmaceutical company, having previously held senior positions at Novartis subsidiaries Advanced Accelerator Applications (AAA), Ipsen and Roche. was
Rafael Ortiz Promoted to Chief Executive Officer (EMEA). Since joining , he has served as Chief Operating Officer (EMEA). January 2022Rafael has over 20 years of experience in the pharmaceutical industry across finance, business development, marketing, sales and general management and previously held senior positions at AAA where he established the radioligand therapeutics business. Asia Pacific region.
Change of company secretary
Telix also announced: Genevieve Ryan As of today, I have been appointed Group Company Secretary. December 5, 2022Mr. Genevieve most recently has 17 years of experience in legal and governance roles at Orora Limited (Orora, ASX: ORA), where he held broad authority as General Counsel for Governance, Corporate & Commercial. . Prior to joining Orora, she worked for Australian Pharmaceutical Industries Limited (API) for almost 10 years where she held roles including senior legal counsel, agency secretary and her Australian compliance officer. new zealand.
Genevieve holds an honors degree in Science and Law from Monash University and a Diploma in Applied Corporate Governance from the US Institute of Governance. AustraliaGenevieve is a Supreme Court solicitor. Victoria and Fellow of the Governance Institute Australiashe exchanges melanie faris He will step down from his role as group company secretary and assume responsibility for a broader portfolio as Senior Vice President of Global Governance, Risk and Compliance (GRC). Melanie has since served as the group company’s secretary. March 2017with over 18 years of experience in governance and corporate operations prior to our listing on the ASX.
Doctor christian berenburg, Telix Group CEO and Managing Director, said: , Raphael, and Melanie, and are pleased to announce their new roles and identify and develop the talent that will support our growing company. Genevieve Ryan As a group company secretary bringing a new and in-depth experience working within an ASX-200 company. “
about Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals. Telix is headquartered in melbourne, australia Developing international business in usa, Europe (Belgium When Switzerland), When JapanTelix develops a portfolio of clinical-stage products aimed at addressing critical unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information, please visit www.telixpharma.com and follow Telix. twitter (@TelixPharma) and LinkedIn.
Gallium-68 (Telix’s flagship product)68Ga) gozetotide (also known as 68Ga PSMA-11) injection is approved by the U.S. Food and Drug Administration (FDA) and[1] and by the Australian Therapeutic Goods Administration (TGA)[2] and by Health Canada.[3]
Telix Investor Information
Mr Kean Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com
This announcement has been approved by the Disclosure Committee of Telix Pharmaceuticals Limited.
legal notice
This announcement can be made in any country in the world ( Australia, America and the England). This announcement may contain forward-looking statements relating to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements generally use words such as “may”, “expect”, “intend”, “plan”, “estimate”, “expect”, “outlook”, “forecast”, ” It can be identified using words such as ‘Guidance’. , or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors and actual results, levels of activity, performance or outcomes may not be expressed or implied by these forward-looking statements. Actual future results, levels of activity, performance or achievements may differ materially. The statement you are looking for. Forward-looking statements are based on our good faith assumptions about financial, market, regulatory and other risks and considerations that exist and may affect our business and operations in the future, any of which may be There is no guarantee of future application. I will prove you right. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements regarding the following: Telix’s ability to advance, enroll and successfully complete product candidates into clinical trials, including multinational clinical trials. the timing or likelihood of regulatory submissions and approvals, manufacturing activities and product marketing activities; commercialization of Telix’s product candidates if approved or if approved; Estimates of Telix’s expenses, future earnings and capital requirements. Telix financial performance. Developments related to Telix’s competitors and industry. Also, pricing and refunds if Telix’s product candidates are approved. Telix’s actual results, performance or achievements may differ materially from those expressed or implied by such statements, and any such differences may be adverse. Therefore, undue reliance should not be placed on these forward-looking statements. This announcement should be read in conjunction with the recent report filed with ASX or the risk factors disclosed on our website.
To the maximum extent permitted by law, Telix undertakes no obligation to publicly update or revise any forward-looking statements contained in this announcement as a result of new information, future developments, or changes in expectations or assumptions. or disavow promises.
The Telix Pharmaceuticals and Illuccix names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates. All rights reserved.
[1] ASX Disclosure December 20, 2021.
[2] ASX Disclosure November 2, 2021.
[3] ASX Disclosure October 14, 2022.
Source Telix Pharmaceuticals Limited